Markets & Finance

UBS Warburg Cuts Cytyc to 'Hold'


UBS Warburg cut Cytyc (CYTC) to hold from buy.

Analyst Ricky Goldwasser says her downgrade reflects a change in the competitive environment for cervical cancer screening. She notes Roche acquired a broad HPV (human papillomavirus) patent portfolio from Institute Pasteur. This means Roche can now develop and commercialize screening tests for HPV that compete with a test that Digene owns.

Goldwasser says Roche told her it plans to introduce a test on the market by the end of 2003. She believes the news could put Cytyc's planned acquisition of Digene at risk. She cut her $23 target to $19.


The Good Business Issue
LIMITED-TIME OFFER SUBSCRIBE NOW

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus